Undisclosed GPC2 ARTEMIS T cell therapy / Eureka Therap, National Cancer Institute - LARVOL DELTA

Eureka’s ARTEMIS CAR T Cells Show Breakthrough Potential in Solid Tumors in NCI-Led Study Published in Cell Reports Medicine (Businesswire) - "ARTEMIS CAR T cells made up 54% of T cells within tumors, compared to just 3% for conventional CAR T cells, representing a 16-fold increase that highlights their superior ability to penetrate solid tumors....In neuroblastoma mouse models with low GPC2 antigen expression, ARTEMIS CAR T cells led to complete tumor regression and 100% survival at week 7. Conventional CAR T cells using the same antigen binder achieved only 50% survival."

Preclinical • Neuroblastoma

Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS T Cell Therapy for Neuroblastoma (Businesswire) - "Eureka Therapeutics, Inc...today announced it has entered into a license agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, for a glypican 2 (GPC2) binding domain to be used for the potential development and commercialization of ARTEMIS^® T cell therapies for patients with neuroblastoma, a rare cancer that affects the developing nervous system. The therapy also has expansion potential in medulloblastoma and small cell lung cancer, among several other pediatric and adult cancers that express an abundance of the GPC2 protein on their cell surface. "

Licensing / partnership • Neuroblastoma • Oncology • Solid Tumor